Literature DB >> 12607595

Expression of vascular endothelial growth factor in invasive ductal carcinoma of the breast and the relation to angiogenesis and p53 and HER-2/neu protein expression.

Ji Shin Lee1, Hyung Seok Kim, Jong Jae Jung, Young Bog Kim, Min Cheol Lee, Chang Soo Park.   

Abstract

The vascular endothelial growth factor (VEGF) appears to play an important role in tumor angiogenesis. The p53 and HER-2/neu genes have been thought to regulate VEGF expression. Although the most common genetic alterations described in human breast cancer are p53 gene mutations and HER-2/neu gene amplification, there is a paucity of reports concerning a possible association between VEGF expression and p53 and HER-2/neu expression. Ninety-nine invasive ductal carcinoma cases were examined by immunohistochemical studies with anti-VEGF, anti-p53, anti-HER-2/neu, and anti-CD34 antibodies. Computerized image analysis was used to evaluate the microvessel density (MVD). Eighty-eight tumors (88.9%) were classified as being VEGF positive. Twenty-five tumors (25.3%) showed p53 protein expression, while 36 tumors (35.4%) expressed the HER-2/neu protein. The MVD ranged from 22.0 to 197.0, with a median value of 58.5 (65.4 +/- 27.9). The tumors expressing VEGF had a significantly higher MVD than those that did not (P < 0.05). VEGF expression was significantly associated with p53 protein expression (P < 0.01). In double VEGF and p53 immunohistochemical stained sections, the two markers were generally expressed in the same tumor cells. The cancer stage was the only independent prognostic factor of disease-free and overall survival. The authors' results suggest that VEGF expression plays a role in promoting angiogenesis in invasive ductal carcinoma of the breast, and p53 is likely to be involved in regulating VEGF expression.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12607595     DOI: 10.1097/00129039-200212000-00001

Source DB:  PubMed          Journal:  Appl Immunohistochem Mol Morphol        ISSN: 1533-4058


  4 in total

Review 1.  Bevacizumab: in first-line treatment of metastatic breast cancer.

Authors:  Lesley J Scott
Journal:  Drugs       Date:  2007       Impact factor: 9.546

2.  Breast Tumor Angiogenesis and Tumor-Associated Macrophages: Histopathologist's Perspective.

Authors:  Ewe Seng Ch'ng; Hasnan Jaafar; Sharifah Emilia Tuan Sharif
Journal:  Patholog Res Int       Date:  2011-06-15

3.  Bcl6/p53 expression, macrophages/mast cells infiltration and microvascular density in invasive breast carcinoma.

Authors:  Roberto Tamma; Simona Ruggieri; Tiziana Annese; Giovanni Simone; Anita Mangia; Serena Rega; Francesco A Zito; Beatrice Nico; Domenico Ribatti
Journal:  Oncotarget       Date:  2018-04-27

Review 4.  p27(Kip1) as a prognostic factor in breast cancer: a systematic review and meta-analysis.

Authors:  Xiaoxiang Guan; Yucai Wang; Ruilian Xie; Longbang Chen; Jianling Bai; Jia Lu; Macus Tien Kuo
Journal:  J Cell Mol Med       Date:  2010-02-27       Impact factor: 5.310

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.